Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Endometrial Neoplasms × Letrozole × Clear all

Phase

Phase 2 13 Phase 1/2 3 Phase NA 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Polycystic Ovary Syndrome 2 Uterine Neoplasms 1 Neoplasm Metastasis 1 Inflammatory Breast Neoplasms 1 Infertility 1 Hydatidiform Mole 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 Gestational Trophoblastic Disease 1 Endometrial Neoplasms 1 Carcinoma, Ductal, Breast 1

Interventions

Paclitaxel 3 Megestrol Acetate 3 Carboplatin 3 Medroxyprogesterone Acetate 2 Cisplatin 2 spartalizumab 1 sintilimab 1 olaparib 1 niraparib 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 durvalumab 1 Tablets 1 Progestins 1 Observation 1 Letrozole 1 Gonadotropin-Releasing Hormone 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡